Arrowhead's long-term chimp study
Markets | Wed Sep 23, 2015 9:19pm EDT
Related: Stocks, Markets, Healthcare
* Announces top-line results from phase 2 trial in patients with liver cirrhosis
* Emricasan significantly lowered portal pressure in patients with severe portal hypertension
* Emricasan met primary endpoints; was found safe and well tolerated in trial Source text for Eikon: Further company coverage:
Intra-Cellular Therapies (ITCI), down 1.73% after filing to sell $300M of common stock...
AMBA had terrible earnings so folks were on the same page, FIT had over the top earnings, stupid to compare AMBA with bad earnings and FIT with hitting it out of the ballpark earnings.
Thanks : )
thats a fact